

- [10] World Health Organization. Make any mother and child count. Geneva; 2005.
- [16] Karron RA. Respiratory syncytial virus and parainfluenza virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed: Saunders- Elsevier, 2008: 1283-93.
- [17] Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. *JAMA* 1999;282:1440-6.
- [19] Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. *J Infect Dis* 1999;179:25-30.
- [188] Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. *Clin Microbiol Rev* 2000;13:371-84.
- [189] Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. *Vaccine* 2007;25:846-55.
- [190] Heilman CA. From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. *J Infect Dis* 1990;161:402-6.
- [191] Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. *J Infect Dis* 1997;175:807-13.
- [192] Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. *J Pediatr* 2003;143:S112-7.
- [193] Hall CB. Respiratory syncytial virus and parainfluenza virus. *N Engl J Med* 2001;344:1917-28.
- [194] Henrickson KJ, Hoover S, Kehl KS, Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. *Pediatr Infect Dis J* 2004;23:S11-8.
- [195] Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. *Am J Dis Child* 1986;140:543-6.
- [196] Silvestri M, Sabatini F, Defilippi AC, Rossi GA. The wheezy infant -- immunological and molecular considerations. *Paediatr Respir Rev* 2004;5 Suppl A:S81-7.
- [197] Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. *Am J Respir Crit Care Med* 2005;171:137-41.
- [198] Smyth RL, Openshaw PJ. Bronchiolitis. *Lancet* 2006;368:312-22.
- [199] Cardenas S, Auais A, Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. *Expert Rev Anti Infect Ther* 2005;3:719-26.
- [200] Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. *J Pediatr* 2007;151:34-42, e1.
- [201] Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? *J Chemother* 2007;19 Suppl 2:8-11.
- [202] Zhao J, Takamura M, Yamaoka A, Odajima Y, Iikura Y. Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood. *Pediatr Allergy Immunol* 2002;13:47-50.
- [203] Matsuse H, Hirose H, Tsuchida T, Fukahori S, Fukushima C, Mizuta Y, et al. Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma. *Allergol Int* 2007;56:165-9.
- [204] Hirose H, Matsuse H, Fukahori S, Tsuchida T, Tomari S, Kawano T, et al. Effects of Repeated Respiratory Syncytial Virus Infections on Pulmonary Dendritic Cells in a Murine Model of Allergic Asthma. *Int Arch Allergy Immunol* 2008;147:197-205.
- [205] Tregoning JS, Yamaguchi Y, Harker J, Wang B, Openshaw PJ. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. *J Virol* 2008;82:4115-24.
- [206] Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. *Am J Epidemiol* 1969;89:449-63.

- [207] Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. *Am J Epidemiol* 1969;89:405-21.
- [208] Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. *Am J Epidemiol* 1969;89:422-34.
- [209] Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. *J Immunol* 2007;179:5415-24.
- [210] Castilow EM, Olson MR, Meyerholz DK, Varga SM. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. *J Virol* 2008;82:2196-207.
- [211] Walsh EE, Falsey AR, Hennessey PA. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. *Am J Respir Crit Care Med* 1999;160:791-5.
- [212] Raboni SM, Nogueira MB, Tsuchiya LR, Takahashi GA, Pereira LA, Pasquini R, et al. Respiratory tract viral infections in bone marrow transplant patients. *Transplantation* 2003;76:142-6.
- [213] Falsey AR, Walsh EE. Respiratory syncytial virus infection in elderly adults. *Drugs Aging* 2005;22:577-87.
- [214] Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med* 2005;352:1749-59.
- [215] Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. *J Infect Dis* 1991;163:693-8.
- [216] Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. *Blood* 2001;98:573-8.
- [217] Cortez KJ, Erdman DD, Peret TC, Gill VJ, Childs R, Barrett AJ, et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. *J Infect Dis* 2001;184:1093-7.
- [218] Collins PL, Chanock RM, Murphy BR. Respiratory syncytial virus. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001.
- [219] Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. *Nat Immunol* 2001;2:732-8.
- [220] Tripp RA, Dakhama A, Jones LP, Barskey A, Gelfand EW, Anderson LJ. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. *J Virol* 2003;77:6580-4.
- [221] Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, Tripp RA. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. *J Immunol* 2006;176:1600-8.
- [222] Li XQ, Fu ZF, Alvarez R, Henderson C, Tripp RA. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. *J Virol* 2006;80:537-40.
- [223] Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. *Clin Microbiol Rev* 2000;13:1-15, table of contents.
- [224] Meyer G, Deplanche M, Schelcher F. Human and bovine respiratory syncytial virus vaccine research and development. *Comp Immunol Microbiol Infect Dis* 2008;31:191-225.
- [225] Lamb RA, Parks GD. Paramyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. *Fields Virology*. Philadelphia: Lippincott, Williams & Wilkins, 2007: 1449-90.
- [226] Nishio M, Ohtsuka J, Tsurudome M, Nosaka T, Kolakofsky D. Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness. *J Virol* 2008;82:6130-8.
- [227] Polack FP, Karron RA. The future of respiratory syncytial virus vaccine development. *Pediatr Infect Dis J* 2004;23:S65-73.

- [228] Walsh EE. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine. *J Infect Dis* 1994;170:345-50.
- [229] Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. *Vaccine* 1996;14:1214-8.
- [230] Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. *Vaccine* 1997;15:1130-2.
- [231] Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. *Vaccine* 2003;21:3465-7.
- [232] Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. *J Infect Dis* 1998;177:467-9.
- [233] Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. *Vaccine* 2003;21:2448-60.
- [234] Ison MG, Mills J, Openshaw P, Zambon M, Osterhaus A, Hayden F. Current research on respiratory viral infections: Fourth International Symposium. *Antiviral Res* 2002;55:227-78.
- [235] Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. *Virology* 1997;230:155-66.
- [236] Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. *J Infect Dis* 2001;184:1456-60.
- [237] Collins PL, Murphy BR. Respiratory syncytial virus: reverse genetics and vaccine strategies. *Virology* 2002;296:204-11.
- [238] Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. *J Infect Dis* 1995;171:1107-14.
- [239] Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. *Pediatr Infect Dis J* 2003;22:394-405.
- [240] Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Robertson D, et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. *J Infect Dis* 2004;189:462-70.
- [241] Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, et al. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. *Vaccine* 2006;24:2432-9.
- [242] Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Jr., Boyce TG, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. *J Infect Dis* 2000;182:1331-42.
- [243] Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. *J Infect Dis* 2005;191:1093-104.
- [244] Wright PF, Karron RA, Madhi SA, Treanor JJ, King JC, O'Shea A, et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. *J Infect Dis* 2006;193:573-81.
- [245] Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, et al. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. *J Infect Dis* 2004;190:2096-103.
- [246] Lee MS, Greenberg DP, Yeh SH, Yogeve R, Reisinger KS, Ward JI, et al. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants. *J Infect Dis* 2001;184:909-13.
- [247] Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogeve R, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. *J Infect Dis* 2005;191:1116-22.

- [248] Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. *J Virol* 2000;74:8922-9.
- [249] Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. *J Virol* 2001;75:4594-603.
- [250] Schmidt AC, Wenzke DR, McAuliffe JM, St Claire M, Elkins WR, Murphy BR, et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. *J Virol* 2002;76:1089-99.
- [251] Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, et al. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. *J Virol* 2004;78:11198-207.
- [252] Crowe JE, Jr., Collins PL, London WT, Chanock RM, Murphy BR. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. *Vaccine* 1993;11:1395-404.
- [253] Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. *J Infect Dis* 1992;166:769-75.
- [254] Voges B, Vallbracht S, Zimmer G, Bossow S, Neubert WJ, Richter K, et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. *Cell Immunol* 2007;247:85-94.
- [255] Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. *Vaccine* 2007;25:8782-93.
- [256] Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. *Vaccine* 2008;26:3480-8.
- [257] Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. *Vaccine* 2007;25:7132-44.
- [258] Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. *J Virol* 2007;81:13710-22.